Solventum (SOLV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Solventum (SOLV) reported $2.1 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 0.7%. EPS of $1.50 for the same period compares to $1.64 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.09 billion, representing a surprise of +0.33%. The company delivered an EPS surprise of +4.9%, with the consensus EPS estimate being $1.43.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Solventum performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales- MedSurg: $1.21 billion compared to the $1.2 billion average estimate based on four analysts. The reported number represents a change of +2% year over year.Net Sales- Purification and Filtration: $128 million versus $213.86 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -46.2% change.Net Sales- Health Information Systems: $345 million versus $337.47 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.8% change.Net Sales- Dental Solutions: $340 million compared to the $318.05 million average estimate based on four analysts. The reported number represents a change of +8.6% year over year.Operating Income- MedSurg: $203 million versus $207.5 million estimated by two analysts on average.Operating Income- Purification and Filtration: $26 million versus $29.51 million estimated by two analysts on average.Operating Income- Health Information Systems: $134 million compared to the $106.94 million average estimate based on two analysts.Operating Income- Dental Solutions: $87 million versus $71.27 million estimated by two analysts on average.View all Key Company Metrics for Solventum here>>>Shares of Solventum have returned -6.5% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Solventum Corporation (SOLV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks